RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
Part of paid clinical trials in East Brunswick, New Jersey.
- Sponsor
- Hoffmann-La Roche
- Study ID
- NCT07413939
- Phase
- PHASE2/PHASE3
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- RO7771950 — DRUGParticipants will receive one of two doses of RO7771950 orally (PO) twice a day (BID).
- Tucatinib — DRUGParticipants will receive a dose of tucatinib PO BID.
- Trastuzumab — DRUGParticipants will receive trastuzumab in accordance with local prescribing information, either through intravenous (IV) or subcutaneously (SC).
- Capecitabine — DRUGParticipants will receive capecitabine according to local prescribing information. Capecitabine will be administered PO BID.
Study Details
The purpose of this study is to assess the efficacy and safety of RO7771950 in combination with trastuzumab and capecitabine, compared to tucatinib in combination with trastuzumab and capecitabine.
Key Dates
- First listed
- Feb 17, 2026
- Start date
- May 21, 2026
- Status verified
- Sep 2026
- Primary completion
- May 1, 2029
- Completion
- Sep 29, 2032
Study Design
- Enrollment
- 650 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm A - RO7771950 Dose Type 1
- Experimental: Arm B - RO7771950 Dose Type 2
- Active Comparator: Arm C - Tucatinib
Primary Outcome Measure
Progression-free Survival (PFS) as Determined by Blinded Independent Central Review (BICR) [ Time Frame: Approximately 35 months ]
Central Contacts
- Reference Study ID Number: WO46069 https://forpatients.roche.com/ No attachments to email below.888-662-6728 (U.S. only)
- Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Astera Cancer Care East Brunswick | East Brunswick | New Jersey | 08816 | - |
| New York Oncology Hematology, P.C. | Albany | New York | 12206 | - |
| New York Cancer and Blood Specialists | Shirley | New York | 11967 | - |
| The West Clinic, PC dba West Cancer Center | Germantown | Tennessee | 38138 | - |
Find similar trials in East Brunswick, NJ
By condition
By specialty
Related Studies
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPHASE2 · Recruiting · QuantumLeap Healthcare Collaborative · Birmingham, Alabama
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PHASE1/PHASE2 · Recruiting · PMV Pharmaceuticals, Inc · La Jolla, California
- Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast CancersPHASE2 · Recruiting · Ruth O'Regan · Chicago, Illinois
- ATEMPT 2.0: Adjuvant T-DM1 vs THPHASE2 · Recruiting · Dana-Farber Cancer Institute · San Francisco, California